Biosimilars

Eledon's tegoprubart gets Orphan Drug status, signaling a new era for liver transplant patients by potentially replacing toxic, decades-old therapies.

Alzheon's pill ALZ-801 shows promise in early AD patients with high genetic risk, offering a potential path that avoids the brain swelling seen in IV drugs.

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

FDA approves Glenmark's generic inhaler with 180-day exclusivity, promising lower costs for millions and disrupting a major respiratory drug market.

Avenacy launches its 26th product, a generic Benadryl injection, tackling drug shortages and aiming to improve patient safety with unique packaging.

With a strong cash position and promising drug candidate, Apogee Therapeutics is advancing multiple trials to challenge the I&I market with a new therapy.

As Cipla rolls out its affordable Liraglutide injection, the battle for the multi-billion dollar GLP-1 market intensifies, promising greater access for patients.

The biopharma firm beats 2025 guidance on strong specialty and generic sales, forecasting another year of growth fueled by new product launches.

Sarepta will unveil crucial long-term data for its Duchenne gene therapy and exon-skipping drugs at MDA 2026, a pivotal moment for patients and the company.

Heron Therapeutics posts record growth fueled by ZYNRELEF and APONVIE, issuing strong 2026 guidance and signaling a successful pivot to profitability.

Eton Pharmaceuticals wins landmark FDA approval for DESMODA, a breakthrough liquid drug set to transform care for a rare condition by enabling precise, safe dosing.

Curanex Pharmaceuticals hits a key manufacturing milestone for Phyto-N, a botanical drug with a 30-year history, advancing its quest for FDA approval.

Promising trial data for onvansertib offers new hope for colorectal cancer patients, yet leadership changes and financial hurdles cloud the path forward.

C4 Therapeutics begins a crucial study for its oral protein degrader, cemsidomide, offering new hope for heavily treated multiple myeloma patients.

The FDA is reviewing a new, more affordable alternative to the costly arthritis drug Orencia, potentially saving patients and the healthcare system billions.

MAIA Pharmaceuticals will bring Teribone™, a proven therapy used in Japan, to the US, aiming to solve the critical patient adherence crisis in osteoporosis care.

With major grants from top foundations, Lario Therapeutics expands its precision neuroscience platform, offering new hope for complex neurological disorders.

New data on Spyre Therapeutics' SPY003 suggests a twice-yearly shot for IBD is possible, part of a broader strategy to challenge market giants.

Anebulo Pharmaceuticals is delisting from Nasdaq to focus on a pediatric cannabis antidote, leaving investors to grapple with an uncertain future.

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.